Upgrade to SI Premium - Free Trial

VIVS (VIVS)

0.46 +0.01 (2.22%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/9/26 *Est.)

Latest Headlines

VivoSim makes first commercial sales in China for NAMkind testing July 21, 2026 8:05 AM - StreetInsider VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services July 21, 2026 8:05 AM - StreetInsider Form 8-K VivoSim Labs, INC. For: Jul 16 July 17, 2026 8:45 AM - SEC Filing VivoSim Labs prices $4M private placement at $0.85 per share July 16, 2026 8:30 AM - StreetInsider VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor July 16, 2026 8:30 AM - StreetInsider Three Biotechs Deliver Catalysts to Watch July 15, 2026 10:43 AM - StreetInsider VivoSim receives $5M milestone payment from Eli Lilly July 15, 2026 8:05 AM - StreetInsider VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 July 15, 2026 8:05 AM - StreetInsider Form 10-K VivoSim Labs, INC. For: Mar 31 July 14, 2026 4:51 PM - SEC Filing Form NT 10-K VivoSim Labs, INC. For: Mar 31 June 29, 2026 4:06 PM - SEC Filing VivoSim presents liver toxicity data at European toxicology conference June 29, 2026 8:05 AM - StreetInsider VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting June 29, 2026 8:05 AM - StreetInsider VivoSim develops AI tool to predict drug-induced diarrhea April 28, 2026 8:05 AM - StreetInsider VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing April 28, 2026 8:05 AM - Globe NewsWire Full Article List